EOCN (36) CVKD (32) GRI (37) ERNA (33) ⌘ Pro Terminal →

60 Degrees Pharmaceuticals Inc. (SXTP) — RQD Stock Rating Cockpit

$0.94 -0.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.94

60 Degrees Pharmaceuticals Inc. (SXTP) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • RED ALERT Cap $3.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SXTP Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-02, 60 Degrees Pharmaceuticals Inc. (NASDAQ: SXTP) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $0.94 (-0.79% 1D, market cap $3.3M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SXTP ranks #597 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SXTP compare to EOCN and CVKD in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SXTP carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of 22.3%, and ROIC of -35.0%. By comparison, EOCN (Eocene Ltd.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and CVKD (Cadrenal Therapeutics Inc.) posts a E grade (32/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M). Among the 5-stock peer group, SXTP leads on earnings multiple (N/A) while SXTP leads on capital efficiency (-35.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SXTP?

▼

Per SXTP's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001946563), 60 Degrees Pharmaceuticals Inc. generated $1.0M in revenue (+65.5% YoY), -$7.4M in net income, and -$7.0M in free cash flow against $5.4M in total assets and $144.0K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $0.94 (-0.33%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-8.5% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SXTP)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (38/100 Composite)

🔍 WHY SXTP SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (29% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 5/9

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (26% of score)

FRED Regime × Technicals: 4% of 52W Range • RSI-14 at 49.4 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)

Disciplined Float (+0.72% YoY Shares) & executive Form 4 sales trim 15 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$0.92-9.8% Next Q

Q2 (-2Q)

Grade E$0.83+4.8% Next Q

Q3 (-1Q)

Grade E$0.87+8% Next Q

Current

Grade D-$0.94-7.8% Hist 90D α

Trajectory: E (30) → D- (38)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SXTP Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SXTP currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.01) and Max Pain ($0.99) forces dealer call-delta covering toward $9.05.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SXTP• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SXTP Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 38%NO 62%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

49.430 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $1$0.94H: $9

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 6 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on SXTP

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (30)

-35.0% ROIC with 22.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 4.20 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (35)

11/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like SXTP

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SXTP)

✓Walkthrough of SXTP's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SXTP // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -41.61%▼ DESCENDING CHANNEL

2026-11-02O $0.85H $0.95L $0.85C $0.94VOL 358.3K

RES: $1.58SUP: $0.56SMA50: $1.01SMA200: $1.77

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SXTP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SXTP Butterfly Map → + Track SXTP →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +65.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SXTP today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SXTP. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SXTP today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SXTP)

Health Care Rank #597 of 1016 ⚔️ EOCN vs SXTP Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SXTP vs. EOCN, CVKD, GRI, ERNA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, 60 Degrees Pharmaceuticals Inc. (SXTP) ranks #597 by composite RQD confidence (38/100, grade D-) and #976 by equity capitalization ($3.3M). Within this direct 5-issuer industry benchmark cohort, SXTP leads on earnings valuation at N/A trailing P/E, while SXTP leads on capital efficiency and profitability with -35.0% ROIC and 22.3% gross margin. SXTP currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SXTP ACTIVE 60 Degrees Pharmaceuticals Inc.	D-	38/100	—	22.3%	-35.0%	-0.79%	$3.3M	Benchmark Subject
EOCN Eocene Ltd.	D-	36/100	—	—	-35.0%	-3.73%	$3.4M	/eocn-vs-sxtp →
CVKD Cadrenal Therapeutics Inc.	E	32/100	—	—	-35.0%	+4.41%	$3.4M	/cvkd-vs-sxtp →
GRI GRI Bio Inc.	D-	37/100	—	—	-35.0%	-2.55%	$3.4M	/gri-vs-sxtp →
ERNA Ernexa Therapeutics Inc.	E	33/100	—	—	-35.0%	-6.63%	$3.4M	/erna-vs-sxtp →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001946563

In its most recent audited fiscal period (FY2025, filed 2025-12-31), 60 Degrees Pharmaceuticals Inc. (SXTP) reported GAAP revenue of $1.0M (+65.5% vs. FY2024 revenue of $607.6K , and +296.5% cumulative change since FY2023) , GAAP net income of -$7.4M, operating cash flow of -$6.8M, and free cash flow of -$7.0M (-21.5% YoY). On the balance sheet, SXTP closed FY2025 with $5.4M in total assets against $144.0K in total debt (Altman Z-Score: N/A, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.0M	-$7.4M	-$6.8M	-$7.0M	$5.4M	$144.0K
FY2024 (FY)	2024-12-31	$607.6K	-$7.9M	-$5.6M	-$5.8M	$5.8M	$147.1K
FY2023 (FY)	2023-12-31	$253.6K	-$3.8M	-$4.5M	-$4.5M	—	—

3. SXTP Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SXTP stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SXTP compare to EOCN and CVKD in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SXTP?

Where is SXTP trading relative to its 50-day, 200-day, and 52-week technical levels?

SXTP last traded at $0.94 (-0.79% on volume of 73,529 shares), positioning the stock -6.93% below its 50-day simple moving average ($1.01) and -46.89% below its 200-day simple moving average ($1.77). Across its 52-week range of $0.59 to $8.62, SXTP sits at the 4.4% percentile with a 14-day RSI of 49.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.06).

SXTP Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SXTP stock right now?

60 Degrees Pharmaceuticals Inc. (SXTP) currently earns a Roarable Rating of D- (Sell — SELL) with 38/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is SXTP's 12-month price target and RQD AI Jury consensus?

SXTP's 12-month base price target is $0.86 (range $0.67 to $9.05), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SXTP RQD Cockpit SXTP 12M Forecast SXTP Earnings & Move SXTP Dividends & DRIP SXTP Insiders & 13F SXTP Whale Options SXTP Profit Sankey SXTP News & Why

ROARABLE RATING BRIEF • RQD 38/100 (D-) ✓ STAGE-C NUMBER FIREWALL VERIFIED

SXTP — 60 Degrees Pharmaceuticals Inc.: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5

As of: 2026-11-02T15:54:04Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SXTP scores 38 / 100 with a letter grade of D-, labeled "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are:

Fundamental Cash Engine: 6 / 20 (ROIC -35%; FCF yield 0%). This is the weakest pillar and reflects negative returns on invested capital and no free-cash-flow yield.
Whale 13F Flow: 6 / 20 (institutional accumulation and options positioning). The rating reflects limited institutional support in the scored data.
Insider Conviction: 5 / 20 (SEC Form 4 and Congressional PTR cluster flow). This is the lowest pillar score and indicates weak insider signal support.
Macro Regime Fit: 10 / 20 (Beta 1.0; sector sensitivity). The beta of 1.0 places the stock in line with the broader market, with no defensive offset.
Forensic Balance Sheet: 11 / 20 (Altman Z 2.5; Piotroski F 5/9; Debt/Equity 0.04). This is the strongest pillar, supported by low reported leverage, though the Altman Z and Piotroski F readings are mid-range rather than strong.

For a prospective investor, the rating points to a company with negative operating economics and cash burn, where the principal support is a low debt load rather than earnings or cash generation. Upside drivers in the source data are limited to catalysts described in the news wire; valuation tradeoffs are severe, since the company is reported at a $3.3M market capitalization with a 52-week range of $0.59 - $8.62. The rating is analytical, not a recommendation.

Business

60 Degrees Pharmaceuticals Inc. (SXTP) is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the company profile. The source data does not describe its specific products, customers, or revenue model. Reported revenue was $1.0M for FY 2025, per the SEC financials. Not available in source data for further detail on how the company earns revenue.

Financial Trend

Period	Revenue	Operating Income	Net Income	EPS	FCF	Cash	Debt
FY 2025	$1.0M	$-7.8M	$-7.4M	N/A	$-7.0M	$1.5M	$0.1M
FY 2024	$0.6M	$-9.7M	$-7.9M	N/A	$-5.8M	$1.7M	$0.1M
FY 2023	$0.3M	$-5.2M	$-3.8M	N/A	$-4.5M	N/A	N/A

Per the SEC financials, revenue rose across the three reported periods while operating and net losses persisted in each year. Per the market data, the gross margin is 22.3%, the operating margin is -60%, the net margin is -60%, and ROIC is -35%. Per the Roarable RQD rating, the Altman Z-Score is 2.5 and the Piotroski F-Score is 5/9, with a Debt/Equity of 0.04. Reported debt is small relative to cash, though cash declined from $1.7M to $1.5M across FY 2024 to FY 2025 while free cash flow remained negative.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts feed (all items tagged to SXTP):

A headline references a January 2027 babesiosis data readout and planned FDA pre-sNDA meeting (flagged YELLOW, market wire).
A headline references the company and Exyn Technologies interviews airing on CNBC and Bloomberg TV (flagged YELLOW, market wire).
A headline reports the stock falling 6% pre-market ahead of tafenoquine trial interim results (flagged RED, risk watch).
A headline describes the stock whipsawing as traders study its financials (flagged YELLOW, market wire).
A headline notes a 30-patient trial remaining blinded as the company plans its next FDA meeting (flagged YELLOW, market wire).
A headline describes the stock grinding higher amid volatile price action (flagged YELLOW, market wire).

Per the Butterfly Supply-Chain Graph, the supply chain is marked NONE, with no butterfly links and no proprietary signals.

Open Questions

What specific products and indications does the company develop, and what stage is each in?
What is the cash runway given $1.5M in reported cash against FY 2025 free cash flow of $-7.0M?
What were the outcomes of the tafenoquine trial interim results referenced in the news feed?
Why are EPS, P/E, and EV/EBITDA not reported, and what share count underlies the $3.3M market capitalization?
What is the status and terms of the planned FDA pre-sNDA meeting?

SXTP Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for 60 Degrees Pharmaceuticals Inc. (SXTP) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SXTP Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 7h ago

60 Degrees Pharmaceuticals Sets January 2027 Babesiosis Data Readout and Plans FDA Pre-sNDA Meeting

Yahoo Finance report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Knoxville News Sentinel • 10h ago

60 Degrees Pharmaceuticals and Exyn Technologies Interviews to Air Nationally on the RedChip Small Stocks, Big Money(TM) Show on CNBC and Bloomberg TV

Knoxville News Sentinel report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH TradingView • 13h ago

60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?

TradingView report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Timothy Sykes • 16h ago

SXTP Stock Whipsaws As Traders Study Deep Red Financials

Timothy Sykes report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 19h ago

A 30-patient trial remains blinded as 60 Degrees Pharma (SXTP) plans its next FDA meeting.

Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE StocksToTrade • 22h ago

SXTP Stock Grinds Higher As Traders Track Volatile Price Action

StocksToTrade report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Stock Titan • 1d ago

All five patients reported improvement; a sensitive post-treatment test found no parasite in four.

Stock Titan report covering 60 Degrees Pharmaceuticals Inc. (SXTP) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Yahoo • 5d ago

60 Degrees Pharmaceuticals Announces Partnership with The University of Southern Mississippi to Evaluate Castanospermine in Nonclinical Models of Alpha-Gal Syndrome

Company plans to explore botanical approval pathways before initiating a prescription drug development programWASHINGTON, Oct. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Com

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SXTP Bull vs. Bear Conversation Board — What's Your Call at $0.94?

🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SXTP 🐻 67% BEARISH CONVICTION

RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $0.84 (-11.6%)

📌 Pinned Debate

🔥 Official Bull vs. Bear Debate: Is SXTP (D- • RQD 38/100) a Buy at $0.95?

Welcome to the SXTP (60 Degrees Pharmaceuticals Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $0.78 (-17.9%)

Spot @ $0.95

Pump the brakes on SXTP — check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SXTP, but look at what you are paying: current EV/EBITDA multiples with 22.3% gross margins. Unless 60 Degrees Pharmaceuticals Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader 🐂 BULLISH 🎯 Target: $1.15 (+21.1%)

Spot @ $0.95

SXTP cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SXTP, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $0.95 (52-wk range $0.59 - $8.62), any beat on forward guidance forces shorts and underweight funds to chase.